Hyperfine, Inc. (HYPR) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Hyperfine, Inc. is an innovative health technology company developing the Swoop® Portable MR Imaging® System, an AI-powered, ultra-low-field (ULF) magnetic resonance device for brain imaging. The company operates as a single reportable segment focused on the production, supply, and commercialization of the Swoop® system. As of March 31, 2026, the company reported 84.2 million shares of Class A common stock and 15.1 million shares of Class B common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $3,903 | $2,137 |
| Gross Profit | $1,979 | $883 |
| Gross Margin | 50.7% | 41.3% |
| Net Loss | $(8,623) | $(9,418) |
| Operating Cash Flow | $(9,008) | $(9,249) |
| Cash and Cash Equivalents | $40,778 | $33,093 |
| Long-Term Debt (Net) | $13,123 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 83% year-over-year to $3.9 million, driven by a 114% increase in device sales ($3.3M vs. $1.5M) and a 67% increase in units sold (10 units vs. 6 units).
- Margin Expansion: Gross margin improved to 50.7% from 41.3% in the prior year, reflecting higher average selling prices and volume efficiencies.
- Expense Reduction: Operating expenses decreased 10.6% to $10.5 million. Research and Development (R&D) expenses dropped 23.7% to $3.8 million, primarily due to lower headcount and stock-based compensation.
- Debt Financing: The company entered a new $40 million senior secured term loan facility in March 2026, drawing $15 million initially. This resulted in $83,000 of interest expense for the quarter, compared to none in the prior year.
- Warrant Liability: The change in fair value of warrant liabilities shifted from a $1.6 million gain in Q1 2025 to a $241,000 loss in Q1 2026.
Guidance, Outlook, and Risks
- Product Milestones: In March 2026, the company received CE Mark and UKCA Mark approval for its next-generation Swoop® scanner and Optive AI™ software. In December 2025, it received FDA clearance for the eleventh-generation software featuring multi-direction DWI sequences for improved stroke detection.
- Liquidity: Management believes existing cash resources ($40.8 million) and the new debt facility are sufficient to fund operations for at least the next 12 months. The company continues to incur net losses and expects to require additional financing in the future.
- Risks: Key risks include the company's history of losses and ability to continue as a going concern, reliance on single-source manufacturers, regulatory approval timelines, and the impact of geopolitical conflicts and inflation on supply chains and costs.
- Grant Funding: The company holds restricted cash of $500,000 related to grants from the Bill & Melinda Gates Foundation (BMGF), with additional funding extending through March 2028.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Horizon Technology Finance Corporation loan covenants, including restrictions on indebtedness and asset dispositions.
- Revenue Concentration: Review the concentration of revenue from top customers (three customers represented >10% of revenue in Q1 2026) and the shift in geographic mix (81.4% U.S. revenue vs. 49.7% in Q1 2025).
- Warrant Liability Volatility: Monitor the fair value of warrant liabilities, which are marked-to-market and can significantly impact net income/loss.
- Going Concern Status: Assess the timeline for achieving profitability given the current burn rate and the company's explicit statement regarding the need for future financing.
- Regulatory Approvals: Track the commercialization impact of the new CE Mark/UKCA approvals for the next-generation scanner in international markets.